vs
Metropolitan Bank Holding Corp.（MCB）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Metropolitan Bank Holding Corp.的季度营收约是RIGEL PHARMACEUTICALS INC的1.3倍（$88.5M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 35.5%，领先348.5%），Metropolitan Bank Holding Corp.同比增速更快（25.4% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 14.3%）
该企业是一家银行控股公司，总部位于马里兰州奥尔尼，业务覆盖华盛顿大都会区。除核心银行业务外，公司还提供商保个人险、保证担保、工伤保险、职业责任险等多种保险产品，同时为高净值个人、企业及机构提供理财规划、财富管理与资产管理服务，2025年4月该公司被收购。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
MCB vs RIGL — 直观对比
营收规模更大
MCB
是对方的1.3倍
$69.8M
营收增速更快
MCB
高出4.2%
21.2%
净利率更高
RIGL
高出348.5%
35.5%
两年增速更快
RIGL
近两年复合增速
14.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $88.5M | $69.8M |
| 净利润 | $31.4M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | 35.5% | 384.0% |
| 营收同比 | 25.4% | 21.2% |
| 净利润同比 | 92.2% | 1769.2% |
| 每股收益（稀释后） | $2.92 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCBRIGL
| Q1 26 | $88.5M | — | ||
| Q4 25 | $88.4M | $69.8M | ||
| Q3 25 | $79.8M | $69.5M | ||
| Q2 25 | $76.3M | $101.7M | ||
| Q1 25 | $70.6M | $53.3M | ||
| Q4 24 | $71.0M | $57.6M | ||
| Q3 24 | $71.5M | $55.3M | ||
| Q2 24 | $67.7M | $36.8M |
净利润MCBRIGL
| Q1 26 | $31.4M | — | ||
| Q4 25 | $28.9M | $268.1M | ||
| Q3 25 | $7.1M | $27.9M | ||
| Q2 25 | $18.8M | $59.6M | ||
| Q1 25 | $16.4M | $11.4M | ||
| Q4 24 | $21.4M | $14.3M | ||
| Q3 24 | $12.3M | $12.4M | ||
| Q2 24 | $16.8M | $-1.0M |
毛利率MCBRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% |
营业利润率MCBRIGL
| Q1 26 | — | — | ||
| Q4 25 | 46.6% | 33.2% | ||
| Q3 25 | 12.8% | 40.9% | ||
| Q2 25 | 35.1% | 60.1% | ||
| Q1 25 | 33.1% | 23.9% | ||
| Q4 24 | 44.1% | 28.9% | ||
| Q3 24 | 24.6% | 25.4% | ||
| Q2 24 | 35.3% | 1.2% |
净利率MCBRIGL
| Q1 26 | 35.5% | — | ||
| Q4 25 | 32.6% | 384.0% | ||
| Q3 25 | 8.9% | 40.2% | ||
| Q2 25 | 24.6% | 58.6% | ||
| Q1 25 | 23.2% | 21.5% | ||
| Q4 24 | 30.2% | 24.9% | ||
| Q3 24 | 17.2% | 22.5% | ||
| Q2 24 | 24.8% | -2.8% |
每股收益（稀释后）MCBRIGL
| Q1 26 | $2.92 | — | ||
| Q4 25 | $2.74 | $14.11 | ||
| Q3 25 | $0.67 | $1.46 | ||
| Q2 25 | $1.76 | $3.28 | ||
| Q1 25 | $1.45 | $0.63 | ||
| Q4 24 | $1.89 | $0.82 | ||
| Q3 24 | $1.08 | $0.70 | ||
| Q2 24 | $1.50 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $948.3M | $391.5M |
| 总资产 | $8.8B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资MCBRIGL
| Q1 26 | — | — | ||
| Q4 25 | $393.6M | $155.0M | ||
| Q3 25 | $385.9M | $137.1M | ||
| Q2 25 | $152.5M | $108.4M | ||
| Q1 25 | $196.5M | $77.1M | ||
| Q4 24 | $200.3M | $77.3M | ||
| Q3 24 | $318.5M | $61.1M | ||
| Q2 24 | $244.7M | $49.1M |
总债务MCBRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M |
股东权益MCBRIGL
| Q1 26 | $948.3M | — | ||
| Q4 25 | $743.1M | $391.5M | ||
| Q3 25 | $732.0M | $117.6M | ||
| Q2 25 | $723.0M | $81.9M | ||
| Q1 25 | $737.8M | $18.6M | ||
| Q4 24 | $729.8M | $3.3M | ||
| Q3 24 | $715.2M | $-14.6M | ||
| Q2 24 | $692.4M | $-29.9M |
总资产MCBRIGL
| Q1 26 | $8.8B | — | ||
| Q4 25 | $8.3B | $513.6M | ||
| Q3 25 | $8.2B | $242.5M | ||
| Q2 25 | $7.9B | $206.7M | ||
| Q1 25 | $7.6B | $176.0M | ||
| Q4 24 | $7.3B | $164.0M | ||
| Q3 24 | $7.4B | $139.4M | ||
| Q2 24 | $7.3B | $128.4M |
负债/权益比MCBRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MCBRIGL
| Q1 26 | — | — | ||
| Q4 25 | $88.7M | $22.0M | ||
| Q3 25 | $31.8M | $24.0M | ||
| Q2 25 | $18.4M | $30.5M | ||
| Q1 25 | $7.8M | $-893.0K | ||
| Q4 24 | $148.5M | $14.5M | ||
| Q3 24 | $4.8M | $21.7M | ||
| Q2 24 | $35.3M | $302.0K |
现金转化率MCBRIGL
| Q1 26 | — | — | ||
| Q4 25 | 3.07× | 0.08× | ||
| Q3 25 | 4.47× | 0.86× | ||
| Q2 25 | 0.98× | 0.51× | ||
| Q1 25 | 0.47× | -0.08× | ||
| Q4 24 | 6.93× | 1.01× | ||
| Q3 24 | 0.39× | 1.75× | ||
| Q2 24 | 2.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
